New Diabetes Drugs Offer Heart Protection, Hope to Patients

Empagliflozin and liraglutide may help protect against serious cardiovascular events, while also helping to lower blood glucose.

The search for diabetes medications that help lower blood glucose levels without adding risks to heart health has been going on for years. Ever since studies linked the popular diabetes drug rosiglitazone (Avandia) with greater heart attack risks about 10 years ago, researchers have been developing a new generation of medications to take its place. Two new drugs have emerged from clinical trials with encouraging results. Empagliflozin and liraglutide have both been shown to reduce the risk of cardiovascular death, while effectively helping to lower blood glucose levels.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access


Please enter your comment!
Please enter your name here